



## Hepatocellular Carcinoma: Current Treatment Strategies for Advanced Disease and Recurrence

Guest Editor:

**Dr. Takefumi Kimura**

Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, Japan

Deadline for manuscript submissions:

**closed (10 January 2024)**

### Message from the Guest Editor

Hepatocellular carcinoma (HCC) treatment options have expanded significantly with the advent of multi-kinase inhibitors and immune checkpoint inhibitors. In addition to drug therapy, there have been remarkable advances in liver transplantation, minimally invasive surgery, the technology involved in ablation therapy, the choice of embolization materials and anticancer drugs for embolization therapy, and radiation therapy. Modern HCC treatment requires not only curative treatment of early-stage lesions, but also the construction of new treatment systems that lead to a cure for advanced HCC and appropriate treatment of recurrent HCC. In addition, NASH and alcoholic liver cancers are expected to increase as viral hepatitis is controlled. The management of side effects in these non-viral HCCs may differ due to differences in drug sensitivity, accompanied with diabetes mellitus and hypertension. In this Special Issue, we call for papers from a wide range of medical, surgical, and radiological perspectives on treatment strategies for advanced disease, approaches to recurrent disease, and management of side effects associated with treatment in the new era of HCC practice.





an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)